Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 2/20 | 0.62 |
| ▸ | JAK3 | P52333 | 7/20 | 0.52 |
| ▸ | JAK2 | O60674 | 6/20 | 0.52 |
| ▸ | JAK1 | P23458 | 2/20 | 0.52 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.49 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.49 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.49 |
| ▸ | SRC | P12931 | 3/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | BTK | Q06187 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14617314 | 1.00 | TGFBR1 (0.62) | TGFBR1JAK3JAK2JAK1FGFR1 | |
| SCHEMBL17267691 | 0.94 | TGFBR1 (0.64) | TGFBR1JAK3JAK2JAK1FGFR1 | |
| SCHEMBL31046956 | 0.94 | TGFBR1 (0.64) | TGFBR1JAK3JAK2JAK1FGFR1 | |
| SCHEMBL17267609 | 0.90 | TGFBR1 (0.54) | TGFBR1JAK3JAK2JAK1FGFR1 | |
| SCHEMBL31046965 | 0.90 | TGFBR1 (0.54) | TGFBR1JAK3JAK2JAK1FGFR1 | |
| SCHEMBL17267741 | 0.89 | TGFBR1 (0.58) | TGFBR1JAK3JAK2JAK1FGFR1 | |
| SCHEMBL2965560 | 0.85 | SRC (0.58) | TGFBR1JAK3JAK2JAK1FGFR1 | |
| SCHEMBL29503478 | 0.85 | SRC (0.58) | TGFBR1JAK3JAK2JAK1FGFR1 | |
| SCHEMBL23150464 | 0.84 | JAK3 (0.59) | TGFBR1JAK3JAK2JAK1FGFR1 | |
| SCHEMBL31071097 | 0.84 | TGFBR1 (0.46) | TGFBR1JAK3JAK2SRCEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4168002-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2023-04-26 | — | — | EP | disclosed |